Localization of the immune response in sarcoidosis

G. W. Hunninghake, J. D. Fulmer, R. C. Young, J. E. Gadek, Ronald Crystal

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Pulmonary sarcoidosis is an interstitial disease characterized by granulomas within the lung parenchyma, anergy to a variety of skin tests, and decreased numbers of circulating T-lymphocytes. To evaluate the effector cell populations present at sites of disease in patients with active pulmonary sarcoidosis, inflammatory and immune effector cells were isolated from lung via bronchoalveolar lavage and compared to comparable cell populations from the peripheral blood of the same patients and similar cell populations of normal subjects and patients with idiopathic pulmonary fibrosis. Patients with sarcoidosis had a marked increase in the percentage of T-lymphocytes in the lung despite a significant peripheral blood T-lymphocytopenia. In addition, many of these T-lymphocytes demonstrated surface marker characteristics associated with lymphocyte activation, and they spontaneously secreted leukocyte inhibitory factor. In contrast to patients with sarcoidosis, normal subjects and patients with idiopathic pulmonary fibrosis had similar percentages of T-lymphocytes in lung and blood, and there was no evidence for T-lymphocyte activation. Analysis of lymphocytes in uninvolved marrow from 7 of 8 patients with sarcoidosis revealed proportions of T-lymphocytes similar to those in the marrows of normal subjects and patients with idiopathic pulmonary fibrosis. In comparison, one patient with sarcoidosis had large numbers of T-lymphocytes in bone marrow, but only in areas where there were granulomas in the marrow. These studies suggest that: the alveolitis of pulmonary sarcoidosis is characterized by large numbers of activated T-lymphocytes, and there is an anatomic localization of the immune response in sarcoidosis in that analysis of uninvolved tissues such as peripheral blood may not reflect local immune responses at sites of granuloma formation.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalAmerican Review of Respiratory Disease
Volume120
Issue number1
Publication statusPublished - 1 Dec 1979
Externally publishedYes

Fingerprint

Sarcoidosis
T-Lymphocytes
Pulmonary Sarcoidosis
Idiopathic Pulmonary Fibrosis
Granuloma
Bone Marrow
Lung
Lymphocyte Activation
Population
Bronchoalveolar Lavage
Skin Tests
Lymphocytes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Hunninghake, G. W., Fulmer, J. D., Young, R. C., Gadek, J. E., & Crystal, R. (1979). Localization of the immune response in sarcoidosis. American Review of Respiratory Disease, 120(1), 49-57.

Localization of the immune response in sarcoidosis. / Hunninghake, G. W.; Fulmer, J. D.; Young, R. C.; Gadek, J. E.; Crystal, Ronald.

In: American Review of Respiratory Disease, Vol. 120, No. 1, 01.12.1979, p. 49-57.

Research output: Contribution to journalArticle

Hunninghake, GW, Fulmer, JD, Young, RC, Gadek, JE & Crystal, R 1979, 'Localization of the immune response in sarcoidosis', American Review of Respiratory Disease, vol. 120, no. 1, pp. 49-57.
Hunninghake GW, Fulmer JD, Young RC, Gadek JE, Crystal R. Localization of the immune response in sarcoidosis. American Review of Respiratory Disease. 1979 Dec 1;120(1):49-57.
Hunninghake, G. W. ; Fulmer, J. D. ; Young, R. C. ; Gadek, J. E. ; Crystal, Ronald. / Localization of the immune response in sarcoidosis. In: American Review of Respiratory Disease. 1979 ; Vol. 120, No. 1. pp. 49-57.
@article{0442f7914dc44af68671c06df948210b,
title = "Localization of the immune response in sarcoidosis",
abstract = "Pulmonary sarcoidosis is an interstitial disease characterized by granulomas within the lung parenchyma, anergy to a variety of skin tests, and decreased numbers of circulating T-lymphocytes. To evaluate the effector cell populations present at sites of disease in patients with active pulmonary sarcoidosis, inflammatory and immune effector cells were isolated from lung via bronchoalveolar lavage and compared to comparable cell populations from the peripheral blood of the same patients and similar cell populations of normal subjects and patients with idiopathic pulmonary fibrosis. Patients with sarcoidosis had a marked increase in the percentage of T-lymphocytes in the lung despite a significant peripheral blood T-lymphocytopenia. In addition, many of these T-lymphocytes demonstrated surface marker characteristics associated with lymphocyte activation, and they spontaneously secreted leukocyte inhibitory factor. In contrast to patients with sarcoidosis, normal subjects and patients with idiopathic pulmonary fibrosis had similar percentages of T-lymphocytes in lung and blood, and there was no evidence for T-lymphocyte activation. Analysis of lymphocytes in uninvolved marrow from 7 of 8 patients with sarcoidosis revealed proportions of T-lymphocytes similar to those in the marrows of normal subjects and patients with idiopathic pulmonary fibrosis. In comparison, one patient with sarcoidosis had large numbers of T-lymphocytes in bone marrow, but only in areas where there were granulomas in the marrow. These studies suggest that: the alveolitis of pulmonary sarcoidosis is characterized by large numbers of activated T-lymphocytes, and there is an anatomic localization of the immune response in sarcoidosis in that analysis of uninvolved tissues such as peripheral blood may not reflect local immune responses at sites of granuloma formation.",
author = "Hunninghake, {G. W.} and Fulmer, {J. D.} and Young, {R. C.} and Gadek, {J. E.} and Ronald Crystal",
year = "1979",
month = "12",
day = "1",
language = "English",
volume = "120",
pages = "49--57",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Localization of the immune response in sarcoidosis

AU - Hunninghake, G. W.

AU - Fulmer, J. D.

AU - Young, R. C.

AU - Gadek, J. E.

AU - Crystal, Ronald

PY - 1979/12/1

Y1 - 1979/12/1

N2 - Pulmonary sarcoidosis is an interstitial disease characterized by granulomas within the lung parenchyma, anergy to a variety of skin tests, and decreased numbers of circulating T-lymphocytes. To evaluate the effector cell populations present at sites of disease in patients with active pulmonary sarcoidosis, inflammatory and immune effector cells were isolated from lung via bronchoalveolar lavage and compared to comparable cell populations from the peripheral blood of the same patients and similar cell populations of normal subjects and patients with idiopathic pulmonary fibrosis. Patients with sarcoidosis had a marked increase in the percentage of T-lymphocytes in the lung despite a significant peripheral blood T-lymphocytopenia. In addition, many of these T-lymphocytes demonstrated surface marker characteristics associated with lymphocyte activation, and they spontaneously secreted leukocyte inhibitory factor. In contrast to patients with sarcoidosis, normal subjects and patients with idiopathic pulmonary fibrosis had similar percentages of T-lymphocytes in lung and blood, and there was no evidence for T-lymphocyte activation. Analysis of lymphocytes in uninvolved marrow from 7 of 8 patients with sarcoidosis revealed proportions of T-lymphocytes similar to those in the marrows of normal subjects and patients with idiopathic pulmonary fibrosis. In comparison, one patient with sarcoidosis had large numbers of T-lymphocytes in bone marrow, but only in areas where there were granulomas in the marrow. These studies suggest that: the alveolitis of pulmonary sarcoidosis is characterized by large numbers of activated T-lymphocytes, and there is an anatomic localization of the immune response in sarcoidosis in that analysis of uninvolved tissues such as peripheral blood may not reflect local immune responses at sites of granuloma formation.

AB - Pulmonary sarcoidosis is an interstitial disease characterized by granulomas within the lung parenchyma, anergy to a variety of skin tests, and decreased numbers of circulating T-lymphocytes. To evaluate the effector cell populations present at sites of disease in patients with active pulmonary sarcoidosis, inflammatory and immune effector cells were isolated from lung via bronchoalveolar lavage and compared to comparable cell populations from the peripheral blood of the same patients and similar cell populations of normal subjects and patients with idiopathic pulmonary fibrosis. Patients with sarcoidosis had a marked increase in the percentage of T-lymphocytes in the lung despite a significant peripheral blood T-lymphocytopenia. In addition, many of these T-lymphocytes demonstrated surface marker characteristics associated with lymphocyte activation, and they spontaneously secreted leukocyte inhibitory factor. In contrast to patients with sarcoidosis, normal subjects and patients with idiopathic pulmonary fibrosis had similar percentages of T-lymphocytes in lung and blood, and there was no evidence for T-lymphocyte activation. Analysis of lymphocytes in uninvolved marrow from 7 of 8 patients with sarcoidosis revealed proportions of T-lymphocytes similar to those in the marrows of normal subjects and patients with idiopathic pulmonary fibrosis. In comparison, one patient with sarcoidosis had large numbers of T-lymphocytes in bone marrow, but only in areas where there were granulomas in the marrow. These studies suggest that: the alveolitis of pulmonary sarcoidosis is characterized by large numbers of activated T-lymphocytes, and there is an anatomic localization of the immune response in sarcoidosis in that analysis of uninvolved tissues such as peripheral blood may not reflect local immune responses at sites of granuloma formation.

UR - http://www.scopus.com/inward/record.url?scp=0018647165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018647165&partnerID=8YFLogxK

M3 - Article

C2 - 313729

AN - SCOPUS:0018647165

VL - 120

SP - 49

EP - 57

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -